MPEP § 2424.02 — “Sequence Listing” Numeric Identifiers
Ninth Edition, Revision 01.2024 · last revised R-07.2022
[Editor Note: This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b). See MPEP §§ 2412-2419 for guidance on WIPO ST.26 requirements for applications filed on or after July 1, 2022.]
37 CFR 1.823(a) sets forth the order and presentation of the items of information in the “Sequence Listing”. Each item of information in the “Sequence Listing” must include the appropriate numeric identifier and its accompanying information as in Appendix G to Subpart G of Part 1. Each item of information must begin on a new line with the numeric identifier enclosed in angle brackets. The submission of those items of information designated with an “M” is mandatory. The submission of those items of information designated with an “O” is optional. Numeric identifiers <110> through <170> must be set forth at the beginning of the “Sequence Listing”.
See MPEP § 2431 for a sample “Sequence Listing”.
Cited authority
- 37 CFR 1.831 Requirements for patent applications filed on or after July 1, 2022, having nucleotide and/or amino acid sequence disclosures
- 2412 The Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures to Include a Sequence Listing in XML file format
- 2419 Publishing of Patent Grants and Patent Application Publications with a “Sequence Listing XML”
- 37 CFR 1.823 Requirements for content of a “Sequence Listing” part of the specification
- 2431 Sample “Sequence Listing” under WIPO ST.25